A. Jackovich

EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma

S. Groshen, T. Dorff, I. Gill, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)

S. Groshen, T. Dorff, D. Quinn, 2021, Annals of Oncology.

EphrinB2: Expression of a novel potential target in renal cell carcinoma

D. Quinn, C. Gupta, S. Sadeghi, 2023, Indian journal of urology : IJU : journal of the Urological Society of India.

EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy.

I. Gill, D. Quinn, C. Gupta, 2020, Pathology, research and practice.

Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma

A. El-Khoueiry, D. Tsao-Wei, A. Jackovich, 2024, Oncotarget.